Raymond James Trust N.A. Sells 12,863 Shares of Envista Holdings Co. (NYSE:NVST)

Raymond James Trust N.A. lessened its stake in Envista Holdings Co. (NYSE:NVST) by 44.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,096 shares of the company’s stock after selling 12,863 shares during the period. Raymond James Trust N.A.’s holdings in Envista were worth $318,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in NVST. Jupiter Asset Management Ltd. bought a new stake in Envista in the 2nd quarter worth approximately $69,534,000. Pacer Advisors Inc. lifted its holdings in shares of Envista by 11,202.8% in the 2nd quarter. Pacer Advisors Inc. now owns 2,887,426 shares of the company’s stock worth $48,018,000 after acquiring an additional 2,861,880 shares during the last quarter. Swedbank AB bought a new stake in shares of Envista in the 1st quarter worth approximately $53,412,000. Nuance Investments LLC grew its holdings in shares of Envista by 47.2% during the 2nd quarter. Nuance Investments LLC now owns 7,038,313 shares of the company’s stock valued at $117,048,000 after purchasing an additional 2,256,993 shares during the last quarter. Finally, Ariel Investments LLC raised its position in Envista by 11.0% in the 2nd quarter. Ariel Investments LLC now owns 9,871,152 shares of the company’s stock worth $164,157,000 after purchasing an additional 978,952 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NVST. Robert W. Baird upped their price target on shares of Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and increased their target price for the company from $16.00 to $23.00 in a report on Thursday, October 31st. JPMorgan Chase & Co. cut Envista from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $23.00 to $16.00 in a research note on Thursday, August 8th. Bank of America cut their target price on shares of Envista from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, Envista currently has a consensus rating of “Hold” and a consensus price target of $20.71.

Envista Stock Performance

Shares of NVST opened at $22.33 on Thursday. The company has a 50-day simple moving average of $19.67 and a two-hundred day simple moving average of $18.24. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The firm has a market capitalization of $3.84 billion, a PE ratio of -2.87, a price-to-earnings-growth ratio of 3.09 and a beta of 1.30. Envista Holdings Co. has a one year low of $15.15 and a one year high of $25.64.

Envista (NYSE:NVST) last released its earnings results on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The company had revenue of $601.00 million during the quarter, compared to analysts’ expectations of $590.34 million. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The firm’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 EPS. On average, analysts anticipate that Envista Holdings Co. will post 0.72 EPS for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.